Literature DB >> 2787972

Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy.

C L Slingluff1, T L Darrow, H F Seigler.   

Abstract

Cytotoxic T lymphocytes (CTL) specific for autologous human melanoma have been generated in vitro from peripheral blood lymphocytes (PBL) of five patients with resectable stage II malignant melanoma. The PBL were cultured with 5u/ml recombinant IL-2 and were repeatedly stimulated with irradiated fresh or cultured autologous tumor cells. Cytotoxicity was determined by four-hour chromium release assays. Specific cytotoxicity developed in 30 to 40 days, after three or four stimulations with tumor. The PBL-derived CTL are CD3+ and are mixed for CD4+ and CD8+ phenotypes. They lysed autologous melanoma and failed to lyse allogeneic melanoma, K562, or autologous lymphocytes. The lysis of autologous tumor was maintained for more than 4 months. The cells proliferated in response to autologous, but not allogeneic melanoma cells, in a dose-dependent manner. Lysis of the autologous tumor target was inhibited with w6/32, a monoclonal antibody to HLA Class I antigens. It is concluded that PBL may serve as a plentiful and renewable source of precursor cells for the generation of autologous tumor-specific CTL, which may be useful in specific adoptive cellular immunotherapy of melanoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787972      PMCID: PMC1357828          DOI: 10.1097/00000658-198908000-00010

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  30 in total

1.  Human tumour antigens defined by cytotoxicity and proliferative responses of cultured lymphoid cells.

Authors:  B M Vose; G D Bonnard
Journal:  Nature       Date:  1982-03-25       Impact factor: 49.962

2.  Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma.

Authors:  T L Darrow; C L Slingluff; H F Seigler
Journal:  Cancer       Date:  1988-07-01       Impact factor: 6.860

3.  Specific selection of cytotoxic effector cells: the generation of cytotoxic T cells in rat thoracic duct lymphocyte populations positively or negatively selected for reactivity to specific strong histocompatibility alloantigens.

Authors:  D B Wilson; A Marshak; G Razzino-Pierson; J C Howard
Journal:  J Immunol       Date:  1976-06       Impact factor: 5.422

4.  Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells.

Authors:  P D Greenberg; M A Cheever
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

5.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

6.  Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.

Authors:  J E de Vries; H Spits
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

7.  Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma.

Authors:  A Anichini; G Fossati; G Parmiani
Journal:  Int J Cancer       Date:  1985-05-15       Impact factor: 7.396

8.  A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.

Authors:  R J Melder; T L Whiteside; N L Vujanovic; J C Hiserodt; R B Herberman
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

9.  Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes.

Authors:  P D Greenberg; M A Cheever; A Fefer
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more
  2 in total

1.  A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).

Authors:  Craig L Slingluff; Sandra Lee; Fengmin Zhao; Kimberly A Chianese-Bullock; Walter C Olson; Lisa H Butterfield; Theresa L Whiteside; Philip D Leming; John M Kirkwood
Journal:  Clin Cancer Res       Date:  2013-05-07       Impact factor: 12.531

Review 2.  Human autologous tumor-specific T cells in malignant melanoma.

Authors:  C D Platsoucas
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.